Results 11 to 20 of about 52,777 (274)

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A. Street, Renee Simms, Leighton E. Clancy, Vicki Antonenas, Brian S. Gloss, Caroline Bateman, David C. Bishop, Kenneth P. Micklethwaite, Emily Blyth   +12 more
wiley   +1 more source

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

American Journal of Hematology, Volume 98, Issue 1, Page 131-139, January 2023., 2023
Abstract Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID‐19. Patients and healthy controls (HC; N = 13) received two doses of BNT162b2: follicular lymphoma (FL; N = 35) who were treatment naïve (TN; N = 11) or received immunochemotherapy (ICT; N = 23) and Waldenström's macroglobulinemia
Brendan Beaton, Sarah C. Sasson, Katherine Rankin, Juliette Raedemaeker, Alexander Wong, Priyanka Hastak, Chansavath Phetsouphanh, Andrew Warden, Vera Klemm, C. Mee Ling Munier, Alexandra Carey Hoppe, Fiona Tea, Aleha Pillay, Alberto Ospina Stella, Anupriya Aggarwal, Orly Lavee, Ian D. Caterson, Stuart Turville, Anthony D. Kelleher, Fabienne Brilot, Judith Trotman   +20 more
wiley   +1 more source

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source

Sex differences in lymphoma incidence and mortality by subtype: A population‐based study

American Journal of Hematology, Volume 98, Issue 1, Page 23-30, January 2023., 2023
A higher incidence and a trend toward higher mortality in men for most lymphoma subtypes is seen in this Swedish population‐based cohort study on adults (age 18‐99) diagnosed with lymphoma 2000‐2019. Male‐to‐female incidence rate ratio (IRR) by male‐to‐female excess mortality ratio (EMR), both adjusted for age and year of diagnosis, by lymphoma subtype.
Cecilia Radkiewicz, Johanna B. Bruchfeld, Caroline E. Weibull, Mathias L. Jeppesen, Henrik Frederiksen, Mats Lambe, Lasse Jakobsen, Tarec C. El‐Galaly, Karin E. Smedby, Tove Wästerlid   +9 more
wiley   +1 more source

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

American Journal of Hematology, Volume 98, Issue 1, Page 193-209, January 2023., 2023
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

American Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P. Treon   +4 more
wiley   +1 more source

The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets

Haematologica, 2012
Background The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them
Francisco de Paula Careta, Stefania Gobessi, Rodrigo Alexandre Panepucci, Engin Bojnik, Fabio Morato de Oliveira, Daniel Mazza Matos, Roberto P. Falcão, Luca Laurenti, Marco A. Zago, Dimitar G. Efremov   +9 more
doaj   +1 more source

Copy-number-variation and copy-number-alteration region detection by cumulative plots [PDF]

BMC Bioinformatics, 10(suppl 1):S67 (2009), 2009
Background: Regions with copy number variations (in germline cells) or copy number alteration (in somatic cells) are of great interest for human disease gene mapping and cancer studies. They represent a new type of mutation and are larger-scaled than the single nucleotide polymorphisms.
arxiv   +1 more source

Monoclonal B-cell lymphocytosis in individuals from sporadic (non-familial) chronic lymphocytic leukemia families persists over time, but does not progress to chronic B-cell lymphoproliferative diseases

Revista Brasileira de Hematologia e Hemoterapia, 2015
BACKGROUND: Monoclonal B-cell lymphocytosis is classified as 'high-count or clinical' monoclonal B-cell lymphocytosis and 'low-count or population' monoclonal B-cell lymphocytosis.
Daniel Mazza Matos, Felipe Magalhães Furtado, Roberto Passetto Falcão   +2 more
doaj   +1 more source